Acquisition Announced

Samsung Biologics Co. acquisition of PolyPeptide Group AG

CHF 1.5bn equity value

Announced 19 Jul 2026 · SIX: PPGN · CHF 44.31 cash per share · 40% premium

Advisers

PolyPeptide Group AG

Target

Not disclosed

Samsung Biologics Co.

Acquirer

Financial adviser
Tax adviser
EY (as Ernst & Young Han Young)
Information agent
Sodali
Target
PolyPeptide Group AG
Acquirer
Samsung Biologics Co.
Target based in
Switzerland
Buyer based in
South Korea
Sector
Pharma Services
Tags
Pharma Services, Contract Manufacturing, Pharmaceutical Manufacturing

Similar deals

All pharma services deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.